Summary

We are waiting for neupro as a new product with long term duration and as a patch  compared to previous dopaminergic available on he market Results are very promising  in both PD and RLS , therefore we need it on the EU MARKET  

Analysis

 We are waiting for neupro as a new product with long term duration and as a patch  compared to previous dopaminergic available on he market Results are very promising  in both PD and RLS , therefore we need it on the EU MARKET

This author consults with leading institutions through GLG

Engage this author or other Neurology experts
 
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.